Search results for "Cyclopropane"

showing 10 items of 104 documents

Effects of exercise training and montelukast in children with mild asthma

2008

Data from the general population suggest that habitual exercise decreases bronchial responsiveness, but the possible role of exercise in asthmatics is undefined. The leukotriene receptor antagonist montelukast decreases bronchial responsiveness and exercise-induced symptoms in asthmatic children. This randomized study in children with mild asthma evaluated the combined effects of aerobic training for 12 wk and montelukast or placebo on bronchial responsiveness (BHR) to methacholine, exercise-induced bronchoconstriction (EIB), inflammatory markers in exhaled breath condensate (EBC), and asthma exacerbations.Fifty children (mean age +/- SD: 10.2 +/- 2.4 yr) with mild stable asthma were random…

CyclopropanesMaleQuinolineAcetatesSettore BIO/09 - Fisiologiaimmune system diseasesMedicineOrthopedics and Sports MedicineAnti-Asthmatic AgentsChildMethacholine ChlorideLeukotrieneeducation.field_of_studyrespiratory systemExercise TherapyAsthma Exercise-InducedBreath TestsItalyExhalationAnesthesiaQuinolinesFemalemedicine.drugHumanmedicine.medical_specialtyBreath TestBronchoconstrictionPopulationPhysical Therapy Sports Therapy and RehabilitationPhysical exerciseSulfidesSettore MED/10 - Malattie Dell'Apparato RespiratorioInternal medicineAerobic exerciseHumansAnti-Asthmatic AgenteducationMontelukastAsthmabusiness.industryLeukotriene receptorAcetateBronchospirometrymedicine.diseaseAsthmarespiratory tract diseasesPhysical FitnessPhysical FitneExercise TestMethacholinebusiness
researchProduct

Can the response to Omalizumab be influenced by treatment duration? A real-life study

2017

Objective It is unknown whether Omalizumab effectiveness changes over the course of time. Our retrospective real-life study tried to analyze whether Omalizumab response may be influenced by treatment duration. Methods 340 severe asthmatics treated with Omalizumab for different periods of time were recruited. They were subdivided into 4 groups according to the Omalizumab treatment length: 60 months. Omalizumab treatment results (FEV1, exacerbations, ACT, SABA use, asthma control levels, medications used e and ICS doses) were compared. Results ACT, exacerbations, GINA control levels, ICS doses and SABA use were similar in all groups with different Omalizumab treatment durations. Using a linea…

CyclopropanesMaleSevere asthmaTime FactorsTreatment durationQuinolineEffectivenessOmalizumabOmalizumabAcetatesAdrenal Cortex Hormone0302 clinical medicineAdrenal Cortex HormonesRetrospective StudieForced Expiratory VolumeMedicinePharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineLead (electronics)Adrenergic beta-AgonistConfoundingEffectiveneReal-lifeResponseAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeEffectiveness; Omalizumab; Real-life; Response; Severe asthma; Treatment duration; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)QuinolinesLinear ModelFemaleHumanmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyTime FactorSulfidesSettore MED/10 - Malattie Dell'Apparato RespiratorioTreatment duration03 medical and health sciencesInternal medicineHumansAnti-Asthmatic AgentMontelukastRetrospective StudiesAsthmaAcetatebusiness.industryBiochemistry (medical)Retrospective cohort studymedicine.diseaseAsthmaDiscontinuationSurgery030228 respiratory systemLinear ModelsbusinessPulmonary Pharmacology & Therapeutics
researchProduct

Enhanced oxidative stress and increased mitochondrial mass during Efavirenz-induced apoptosis in human hepatic cells

2010

BACKGROUND AND PURPOSE Efavirenz (EFV) is widely used in the treatment of HIV-1 infection. Though highly efficient, there is growing concern about EFV-related side effects, the molecular basis of which remains elusive. EXPERIMENTAL APPROACH In vitro studies were performed to address the effect of clinically relevant concentrations of EFV (10, 25 and 50 mu M) on human hepatic cells. KEY RESULTS Cellular proliferation and viability were reduced in a concentration-dependent manner. Analyses of the cell cycle and several cell death parameters (chromatin condensation, phosphatidylserine exteriorization, mitochondrial proapoptotic protein translocation and caspase activation) revealed that EFV tr…

CyclopropanesMalehepatotoxicityCarcinoma HepatocellularTime FactorsAnti-HIV AgentsCell SurvivalApoptosisMitochondria LiverPhosphatidylserinesAntioxidantsSuperoxidesHumansChromansantiretroviral drugsCell Proliferationreactive oxygen speciesDose-Response Relationship DrugCell CycleLiver NeoplasmsChromatin Assembly and DisassemblyResearch PapersGlutathioneBenzoxazinesmitochondriaOxidative Stressside effectscell deathLiverAlkynesFemaleEfavirenzApoptosis Regulatory ProteinsHeLa Cells
researchProduct

Pharmacokinetic interaction between efavirenz and ketoconazole in rats

2009

It is well known that efavirenz and ketoconazole act as an inducer and inhibitor of CYP3A4, respectively. As a result of these actions, co-administration of these drugs may result in changes in the pharmacoki- netic parameters of one or both of them. 2. Duodenum-cannulated rats have been used to compare the effect of intraduodenal (KC i.d. ) and intrave- nous administration of ketoconazole (KC i.v. ) on the pharmacokinetics of efavirenz after intraduodenal administration, as well as the potential effect of efavirenz as a CYP450 inducer on ketoconazole phar - macokinetic profile. 3. While KC i.v. did not show any significant effect on efavirenz pharmacokinetic profile, KC i.d. increased sig-…

CyclopropanesMalemedicine.medical_specialtyAntifungal AgentsEfavirenzAnti-HIV AgentsHealth Toxicology and MutagenesisPharmacologyToxicologyBiochemistryEnteral administrationDrug Administration SchedulePeak concentrationchemistry.chemical_compoundCytochrome P-450 Enzyme SystemPharmacokineticsimmune system diseasesInternal medicinemedicineAnimalsCytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsDrug InteractionsInducerRats WistarPharmacologyCYP3A4Chemistryvirus diseasesGeneral MedicineBenzoxazinesRatsKetoconazoleEndocrinologyAlkynesKetoconazolePharmacokinetic interactionmedicine.drugXenobiotica
researchProduct

Inhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations.

2015

ABSTRACT Between 22 and 45% of HIV-positive subjects are likely to report symptoms of depression. Considering this background, a potential pharmacokinetic interaction between the nonnucleoside reverse transcriptase inhibitor efavirenz (EFV) and two antidepressants, sertraline (SRT) and nortriptyline (NT), was studied. Rats were administered EFV alone or together with the antidepressants, and changes in the plasma levels and pharmacokinetic parameters of EFV were analyzed. Additional in vitro experiments with rat and human hepatic microsomes were carried out to evaluate the inhibitory effect of SRT and NT on EFV metabolism by determining the formation rate of the major EFV metabolite (8-OH-E…

CyclopropanesMalemedicine.medical_specialtyEfavirenzAnti-HIV AgentsMetaboliteNortriptylinePharmacology030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsIn vivoInternal medicineSertralinemedicineAnimalsHumansPharmacology (medical)Drug Interactions030212 general & internal medicineRats WistarIC50PharmacologyChemistryAntidepressive AgentsBenzoxazinesInfectious DiseasesEndocrinologyAlkynesMicrosomeMicrosomes LiverReverse Transcriptase InhibitorsNortriptylinehuman activitiesDrug metabolismmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the E…

2022

Background and aim: Direct Acting Antivirals(DAAs) achieve the highest rate of sustained viral re- sponse(SVR) in patients with genotype-1b(G1b) Hepatitis C virus(HCV) infection. Reducing treatment du- ration can simplify the management and improve adherence of therapy. Patients and methods: The study evaluates the efficacy of 8 weeks of elbasvir/grazoprevir regimen in 75 treatment-naïve(TN), G1b patients with mild-moderate fibrosis(Liver Stiffness by Fibroscan®< 9.0 kPa). Viral load(VL) has been evaluated by Roche TaqMan RT-PCR(LLOQ < 15 IU/ml). Results: Mean age was 61.0 ±14.2 years, 44% were male, mean LS by Fibroscan®was 6.1 ±1.8 kPa. Twenty-eight patients(37.3%) had an HOMA > …

CyclopropanesMalemedicine.medical_specialtyElbasvirGenotypeHepatitis C virusHepacivirusmedicine.disease_causeGastroenterologyAntiviral AgentsSettore MED/07Insulin resistanceFibrosisInternal medicineQuinoxalinesRibavirinmedicineElbasvir GrazoprevirHumansAgedBenzofuransSulfonamidesHepatologybusiness.industryGastroenterologyImidazolesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseAmidesHepatitis CSustained virological responseRegimenGlucoseGrazoprevirHCVRNADrug Therapy CombinationFemaleCarbamatesSafetyLiver stiffnessbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury

2009

Mandarin translation of abstract Background and purpose:  The effects of a phosphodiesterase 4 (PDE4) inhibitor, roflumilast, on bleomycin-induced lung injury were explored in ‘preventive’ and ‘therapeutic’ protocols and compared with glucocorticoids. Experimental approach:  Roflumilast (1 and 5 mg·kg−1·d−1, p.o.) or dexamethasone (2.5 mg·kg−1·d−1, p.o.) was given to C57Bl/6J mice from day 1 to 14 (preventive) or day 7 to 21 (therapeutic) after intratracheal bleomycin (3.75 U·kg−1). In Wistar rats, roflumilast (1 mg·kg−1·d−1, p.o.) was compared with methylprednisolone (10 mg·kg−1·d−1, p.o.) from day 1 to 21 (preventive) or from day 10 to 21 (therapeutic), following intratracheal instillatio…

CyclopropanesMalemedicine.medical_specialtyPhosphodiesterase InhibitorsPulmonary FibrosisAminopyridinesLung injuryBiologyBleomycinBronchoalveolar Lavagechemistry.chemical_compoundBleomycinMiceFibrosisRight ventricular hypertrophyInternal medicinePulmonary fibrosismedicineAnimalsRats WistarLungDexamethasoneRoflumilastPharmacologymedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionLung Injuryrespiratory systemmedicine.diseaseResearch Papersrespiratory tract diseasesRatsMice Inbred C57BLDisease Models AnimalBronchoalveolar lavageEndocrinologychemistryBenzamidesPhosphodiesterase 4 InhibitorsBronchoalveolar Lavage Fluidmedicine.drug
researchProduct

Synthesis of oxaspiranic compounds through [3 + 2] annulation of cyclopropenones and donor–acceptor cyclopropanes.

2014

The Sc(OTf)3-catalyzed [3 + 2]-annulation reaction between cyclopropenones and donor–acceptor cyclopropanes is described. The process leads directly to the formation of 4-oxaspiro[2.4]hept-1-ene derivatives in good to excellent reaction yields. Density functional theory calculations suggest that the [3 + 2]-annulation pathway is strongly preferred over the possible [3 + 3]-process.

CyclopropanesMesylatesAnnulationMolecular StructureChemistryOrganic ChemistryStereoisomerismCatalysisComputational chemistryDensity functional theorySpiro CompoundsCycloheptanesDonor acceptorScandiumThe Journal of organic chemistry
researchProduct

Enantio- and diastereocontrol in intermolecular cyclopropanation reaction of styrene catalyzed by dirhodium(II) complexes with bulky ortho-metalated …

2004

Enantiomerically pure dirhodium(II) complexes with ortho-metalated p-substituted aryl phosphines have been shown to be enantio- and diastereoselective in the cyclopropanation of styrene by ethyl diazoacetate. Enantioselectivities up to 91% and diastereoselectivities up to 90% are observed for ethyl cis-2-phenylcyclopropanecarboxylate. Estevan Estevan, Francisco, Francisco.Estevan@uv.es ; Lahuerta Peña, Pascual, Pascual.lahuerta@uv.es ; Lloret Fillol, Julio, Julio.Lloret@uv.es ; Sanau Torrecilla, Mercedes, Mercedes.Sanau@uv.es ; Ubeda Picot, M Angeles, Angeles.Ubeda@uv.es ; Vila Gomez, Jaume Llorenc, Jaume.Vila@uv.es

CyclopropanesModels MolecularReactionPhosphinesCyclopropanationUNESCO::QUÍMICAIntermolecularCrystallography X-RayMedicinal chemistryHydrocarbons Aromatic:QUÍMICA [UNESCO]CatalysisStyrenesCatalysisStyrenechemistry.chemical_compoundEthyl diazoacetateOrganometallic CompoundsMaterials ChemistryOrganic chemistryRhodiumIntermolecular ; Reaction ; Dirhodium ; Phosphines ; CyclopropanationMolecular StructureCyclopropanationArylIntermolecular forceUNESCO::QUÍMICA::Química analíticaMetals and AlloysStereoisomerismGeneral MedicineGeneral ChemistryDirhodiumSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialschemistryCyclization:QUÍMICA::Química analítica [UNESCO]Ceramics and Composites
researchProduct

Involvement of nitric oxide in the mitochondrial action of efavirenz: a differential effect on neurons and glial cells

2014

Abstract The anti-human immunodeficiency virus (HIV) drug efavirenz (EFV) alters mitochondrial function in cultured neurons and glial cells. Nitric oxide (NO) is a mediator of mitochondrial dysfunction associated with HIV central nervous system symptoms. We show that EFV promotes inducible nitric oxide synthase (iNOS) expression in cultured glial cells and generated NO undermines their mitochondrial function, as inhibition of NOS partially reverses this effect. EFV inhibits mitochondrial Complex I in both neurons and glia; however, when the latter cells are treated for longer periods, other mitochondrial complexes are also affected in accordance with the increased NO production. These findi…

CyclopropanesNNRTIEfavirenzAnti-HIV AgentsCentral nervous systemNitric Oxide Synthase Type IIMitochondrionBiologyNitric OxideNitric oxideCell Linechemistry.chemical_compoundMediatornitric oxidemedicineImmunology and AllergyHumansNeuronsNeurotoxicityelectron transport chainHIVefavirenzmedicine.diseasecentral nervous systemCell biologyBenzoxazinesMitochondriaNitric oxide synthasemitochondriaInfectious Diseasesmedicine.anatomical_structurechemistryAlkynesImmunologybiology.proteinNeurogliaNeuroglia
researchProduct